Answers are grounded in this paper and cite their sources.
OBJECTIVE: This study preliminarily evaluated the prognostic value of the inflammation-immunity-nutrition score (IINS) in advanced NSCLC patients receiving first-line immunotherapy. METHODS: This retrospective, single-center study enrolled 212 patients. Patients were categorized into the death group, survival group, progressive disease (PD) group, and non-PD (N-PD) group. Prognosis analysis employed Cox regression, Kaplan-Meier (KM) survival curves, and ROC curves. Internal validation was performed using the Bootstrap method and a 10-fold cross-validation approach, and calibration curves were plotted. RESULTS: High IINS was associated with poorly differentiated tumors, stage IV disease, and ≥2 metastases. Patients with PD or death had significantly higher IINS. After adjusting for available confounding factors, a higher IINS remained associated with PD and death. IINS may aid in the prognostic assessments of PD and death within 3 years, with good model performance in internal validation. High-risk patients showed reduced survival. CONCLUSION: Higher IINS correlates with poor 3-year prognosis. Given the limitations of the retrospective, single-center design, the absence of a non-immunotherapy control group, and the failure to adjust for certain key confounding factors, the above conclusions should be regarded as preliminary, hypothesis-generating findings that require external validation through prospective, multicenter studies.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: